
Epigenomic Toolset

Mapping the Ontogenetic Pathways of Cellular Differentiation from the Human Epigenome Atlas Data Using the **Epigenomic Toolset** Within the Genboree Workbench

> Aleks Milosavljevic Baylor College of Medicine

Epigenomics: A Roadmap to the Living Genome Boston, October 22nd, 2013

Acknowledgements




The scope of the Epigenomic Toolset

Phylogeny

Reconstruct ontogeny

Ontogenetic pathways of cellular differentiation

Interpret epigenomic perturbations Disease-associated




1. Identify cell-type specific epigenomic states

- 2. Inform experiment design by identifying informative marks
- 3. Interpret epigenomic changes during cellular differentiation
- **4.** Detect and interpret epigenomic perturbations in disease (cancer cells) relative to epigenomes of normal cells
- **5.** Detect shifts in cell type composition in complex tissues (tumor vs. normal) using epigenomes of constituent cells

Epigenomic Data Slice

Regions Of Interest (ROIs) (enhancers, promoters, ChIP-seq peaks, etc.)





Epigenomic marks (e.g., histone marks)

Epigenomic Data Slice


AM 10/21/2013

Heatmaps and Dendograms












Genboree is built & maintained by the Bioinformatics Research Laboratory at Baylor College of Medicine.




Genboree is a hosted service. Code is available free for academic use.

Dendogram of 100 epigenomes constructed from ~0.5M enhancers and H3K4me1

Immune
 Endoderm
 Cardiac
 StemCells
 Ectodermal Epithelial
 Gastrointestinal
 Brain
 Fetal Organs
 Mesenchymal Stem Cells



ROIs with lineage-specific active epigenomic marks



1. Identify cell-type specific epigenomic states

2. Inform experiment design by identifying informative marks

3. Interpret epigenomic changes during cellular differentiation


4. Detect and interpret epigenomic perturbations in disease (cancer cells) relative to epigenomes of normal cells

5. Detect shifts in cell type composition in complex tissues (tumor vs. normal) using epigenomes of constituent cells

Recurrent tree branches


H3K4me3 signal over promoters

H3K4me1 signal over lincRNA Transcription Start Site (TSS)



Hypothesis: a branch shared by many trees (*confirmed by many mark-ROI combinations*) corresponds to an ontogenetic pathway

Informative epigenomic marks and mark-ROI combinations



1. Identify cell-type specific epigenomic states


2. Inform experiment design by identifying informative marks

3. Interpret epigenomic changes during cellular differentiation


4. Detect and interpret epigenomic perturbations in disease (cancer cells) relative to epigenomes of normal cells

5. Detect shifts in cell type composition in complex tissues (tumor vs. normal) using epigenomes of constituent cells

Mapping epigenomic changes using Spark tool




Pathway enrichment using H3K4me1 over enhancers and GREAT tool



AM 10/21/2013

GWAS regions enriched for enhancers with **immune-lineage specific** H3K4me1 mark



Fold enrichment

1. Identify cell-type specific epigenomic states


2. Inform experiment design by identifying informative marks

3. Interpret epigenomic changes during cellular differentiation

4. Detect and interpret epigenomic perturbations in disease (cancer cells) relative to epigenomes of normal cells


5. Detect shifts in cell type composition in complex tissues (tumor vs. normal) using epigenomes of constituent cells

Dendogram including HL-60, a *promyelocytic leukemia* cell line confirms *myeloid lineage*



Spark analysis involving closest reference epigenomes reveals lack of differentiation

Epigenomic patterns over 1025 enhancers that change epigenomic state during myeloid differentiation



Pathway analysis reveals up-regulation of oncogenetic pathways

Analysis of enhancers with up-regulated H3K4me1 using GREAT tool

-log10(Binomial p value)

0 1 2 3 4 5 6 7 8 TNF receptor signaling pathway 8.18 Regulation of nuclear SMAD2/3 signaling 8.18 8.18 Regulation of cytoplasmic and nuclear SMAD2/3 signaling 8.18 8.18 ALK1 signaling pethway 8.18 8.04 p38 MAPK signaling pathway 8.00 8.00 ALK1 pathway 8.00 8.00 BMP receptor signaling 7.54 Regulation of p38-alpha and p38-beta 6.76 Wht signaling network 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulated gene expr			logio(biloniai p valae)							
IGF-beta receptor signaling 8.18 Regulation of nuclear SMAD2/3 signaling 8.18 Regulation of cytoplasmic and nuclear SMAD2/3 signaling 8.18 ALK1 signaling events 8.04 p38 MAPK signaling pathway 8.00 ALK1 pathway 7.93 IL1-mediated signaling events 7.68 BMP receptor signaling 7.54 Regulation of p38-alpha and p38-beta 6.76 Wnt signaling events 6.76 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51		0	1	2	3	4	5	6	7	8
Regulation of nuclear SMAD2/3 signaling 8.18 Regulation of cytoplasmic and nuclear SMAD2/3 signaling 8.18 ALK1 signaling events 8.04 p38 MAPK signaling pathway 8.00 ALK1 pathway 7.93 IL1-mediated signaling events 7.68 BMP receptor signaling 7.54 Regulation of p38-alpha and p38-beta 6.76 Wnt signaling events 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51	TNF receptor signaling pathwa	y								8.66
Regulation of cytoplasmic and nuclear SMAD2/3 signaling 8.18 ALK1 signaling events 8.04 p38 MAPK signaling pathway 8.00 ALK1 pathway 7.93 IL1-mediated signaling events 7.68 BMP receptor signaling 7.54 Regulation of p38-alpha and p38-beta 6.76 Wnt signaling network 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51										
ALK1 signaling events 8.04 p38 MAPK signaling pathway 8.00 ALK1 pathway 7.93 IL1-mediated signaling events 7.68 BMP receptor signaling 7.54 Regulation of p38-alpha and p38-beta 6.76 Wnt signaling network 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51										
p38 MAPK signaling pathway ALK1 pathway IL1-mediated signaling events BMP receptor signaling Regulation of p38-alpha and p38-beta Wnt signaling network Syndecan-4-mediated signaling events Glypican 3 network Signal regulatory protein (SIRP) family interactions PERK regulated gene expression C-MYB transcription factor network IRAK2 mediated activation of TAK1 complex 2.51										
ALK1 pathway 7.93 IL1-mediated signaling events 7.68 BMP receptor signaling 7.54 Regulation of p38-alpha and p38-beta 6.76 Wnt signaling network 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51										
IL1-mediated signaling events 7.68 BMP receptor signaling 7.54 Regulation of p38-alpha and p38-beta 6.76 Wnt signaling network 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51										8.00
BMP receptor signaling 7.54 Regulation of p38-alpha and p38-beta 6.76 Wnt signaling network 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 6.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51	ALK1 pathwa	y								7.93
Regulation of p38-alpha and p38-beta 6.76 Wnt signaling network 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51	IL1-mediated signaling event	S								7.68
Wnt signaling network 6.08 Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51										7.54
Syndecan-4-mediated signaling events 5.40 Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51	Regulation of p38-alpha and p38-bet	a							6.76	5
Glypican 3 network 5.30 Signal regulatory protein (SIRP) family interactions 4.82 PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51	Wnt signaling networ	k						6.	08	
Signal regulatory protein (SIRP) family interactions PERK regulated gene expression C-MYB transcription factor network IRAK2 mediated activation of TAK1 complex 2.51	Syndecan-4-mediated signaling event	s						5.40		
PERK regulated gene expression 4.52 C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51	Glypican 3 networ	k						5.30		
C-MYB transcription factor network 2.90 IRAK2 mediated activation of TAK1 complex 2.51							4.82	2		
IRAK2 mediated activation of TAK1 complex 2.51	PERK regulated gene expressio	n					4.52			
	C-MYB transcription factor networ	k			2.90					
					2.51					
AKZ mediated activation of TAKI complex upon TLR7/8 or 9 stimulation 2.51	IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulatio	n			2.51					
Beta5 beta6 beta7 and beta8 integrin cell surface interactions 2.43	Beta5 beta6 beta7 and beta8 integrin cell surface interaction	S			2.43					

1. Identify cell-type specific epigenomic states


2. Inform experiment design by identifying informative marks

3. Interpret epigenomic changes during cellular differentiation


4. Detect and interpret epigenomic perturbations in disease (cancer cells) relative to epigenomes of normal cells

5. Detect shifts in cell type composition in complex tissues (tumor vs. normal) using epigenomes of constituent cells


Samples from pure cell types



Samples from a complex tissue




Tumor vs. normal tissue



Marker CpGs for Illumina arrays


LIMMA tool within the Genboree Workbench used to select **marker CpGs** that show lineage-specific methylation

- Illumina 450k array CpGs
- Illumina 27k array CpGs
- Shared 450K and 27K array CpGs




Tracks with Illumina marker CpGs available at <u>www.genboree.org</u> (Use case 21)

Comparison against reference epigenomes



Comparison against reference epigenomes



Comparing methylation arrays against the methylomes in the Epigenome Atlas

Step 1:

Array import via the Genboree Workbench:

GENBOF	REE			Baylor College of Medicine				
System/Network	sing • Genome •	Transcriptome Cistrome	Epigenome - Metagenome -	Visualization - Help -				
Welcome to	pench! [Getting St	tarted]						
Data Selector Entrypoints		Details						
SRefresh	ata Filter: Select a filter Value							
▲ I www.genbo		*						
Aleks_gro Bamples & Sample Sets		-						
▷ 🛃 AleksG ▷ 🛃 ARJ	🚍 Import 🕨 🐻 A	Array Data						
⊳ 🝰 ARJ2	Utilities 🕨 📝 T	rack Metad Array Data						
▷ 🛃 arpit_group ▷ 📌 Atlas Tools Access	Ξ. υ	Ipload Track Import array data inte	Genboree as a high density track.					
BCM-MDA SOLID Matenairs								
⊳ 🛃 BioMarkers		± ∓ X						
⊳ 🝰 Bios-533-2005								

1. Identify cell-type specific epigenomic states


2. Inform experiment design by identifying informative marks

3. Interpret epigenomic changes during cellular differentiation


4. Detect and interpret epigenomic perturbations in disease (cancer cells) relative to epigenomes of normal cells

5. Detect shifts in cell type composition in complex tissues (tumor vs. normal) using epigenomes of constituent cells

Virtual integration across the International Human Epigenome Consortium (IHEC)



Virtual integration



- **1.** Identify cell-type specific epigenomic states
- 2. Inform experiment design by identifying informative marks
- 3. Interpret epigenomic changes during cellular differentiation
- **4.** Detect and interpret epigenomic perturbations in disease (cancer cells) relative to epigenomes of normal cells
- **5.** Detect shifts in cell type composition in complex tissues (tumor vs. normal) using epigenomes of constituent cells



Human Epigenome Atlas and Epigenomic Profile Analysis Using the Genboree Workbench

Separate advance registration required. Please check the appropriate box on the meeting registration form.

Tuesday, October 22

2:00 pm – 3:30 pm

Room 104AB, Level 1, Convention Center

